← FDA DRUG APPROVALS

FDA ANDA · ANDA065013

TOBRAMYCIN

Sponsor: XGEN PHARMS

APPLICATION
ANDA065013
TYPE
ANDA
ORIGINAL APPROVAL
2001-08-17
LATEST ACTION
2023-08-29
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

TOBRAMYCIN SULFATEPrescription
TOBRAMYCIN SULFATE EQ 1.2GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2023-08-29Labeling · Supplement 17 · standardAP
2023-02-10Labeling · Supplement 16 · standardAP
2013-10-07Manufacturing (CMC) · Supplement 10AP
2013-08-16Labeling · Supplement 12 · standardAP
2012-11-09Labeling · Supplement 11 · standardAP
2012-10-31Labeling · Supplement 9AP
2012-01-17Labeling · Supplement 7LabelAP
2010-10-18Labeling · Supplement 8AP
2002-12-09Manufacturing (CMC) · Supplement 2AP
2001-08-17OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →